Evenity (Romosozumab) Cost in Oregon 2026

What Does Evenity (Romosozumab) Cost in Oregon?

Evenity carries a manufacturer list price of $1,825 per monthly injection as of 2026, making a full 12-dose course approximately $21,900 before insurance, discounts, or assistance programs. Cash-pay prices at Oregon retail pharmacies mirror the list price closely because romosozumab has no generic equivalent and only one biosimilar pathway is currently under development. Patients without adequate coverage face the full burden unless they qualify for manufacturer assistance or Oregon Health Plan.

List Price vs. What Oregon Patients Actually Pay

The $1,825 list price is a starting point, not a ceiling. Commercially insured Oregon patients with the Amgen/UCB savings card can pay as little as $0 per month, subject to eligibility criteria. Oregon Health Plan enrollees with a confirmed prior authorization pay nothing at the pharmacy counter. The gap between list price and net patient cost varies dramatically depending on plan type, deductible status, and whether the medication is administered in a physician office (medical benefit) or dispensed at a pharmacy (pharmacy benefit).

Romosozumab is FDA-approved specifically for postmenopausal women with osteoporosis at high or very high risk of fracture, defined in the prescribing label as a history of osteoporotic fracture, multiple risk factors for fracture, or failure or intolerance to other osteoporosis therapy. The full prescribing information is maintained on the FDA accessdata portal.

Why Romosozumab Is Priced at a Premium

Romosozumab is a sclerostin inhibitor. It works by blocking sclerostin, a protein that suppresses bone formation, so it simultaneously increases bone formation and decreases bone resorption. That dual mechanism is unlike bisphosphonates or denosumab, and the clinical data support faster bone mineral density (BMD) gains. In the FRAME trial (N=7,180), romosozumab 210 mg monthly produced a 13.3% increase in lumbar spine BMD at 12 months compared with placebo [1]. That kind of efficacy at speed justifies the premium pricing, but it also means payers demand thorough documentation before approving the drug.

Oregon Medicaid (OHP) Coverage for Romosozumab

Oregon Health Plan (OHP) covers Evenity for severe osteoporosis with prior authorization. Coverage is not automatic. The prescribing clinician must submit clinical documentation showing the patient meets OHP's criteria, which typically require a DXA-confirmed T-score of -2.5 or below, evidence of high fracture risk, and prior trial of a bisphosphonate or documented intolerance. The NIH Osteoporosis and Related Bone Diseases Resource Center outlines fracture risk stratification thresholds that align with OHP criteria.

Prior Authorization Requirements for OHP

Oregon's Fee-For-Service Medicaid program and most OHP coordinated care organizations (CCOs) apply the following criteria for romosozumab approval:

• DXA T-score at lumbar spine or total hip of -2.5 or below, OR documented fragility fracture within 24 months
• Trial and failure of at least one oral bisphosphonate (alendronate or risedronate) for a minimum of 12 months, or documented contraindication or intolerance
• No history of myocardial infarction or stroke within the prior 12 months (FDA black-box warning requirement)
• Prescription written by or in consultation with an endocrinologist, rheumatologist, or osteoporosis-specialist clinician

The cardiovascular restriction is non-negotiable. The FDA label carries a boxed warning stating that romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death. Patients with a prior MI or stroke should not receive romosozumab. The FDA drug safety communication covering this warning is indexed at accessdata.fda.gov.

What Happens After OHP Approves the PA

Once OHP approves the prior authorization, the drug is typically dispensed through a specialty pharmacy contracted with the CCO. The patient's cost share at point of dispensing is $0 for most OHP enrollees. The 12-month course is then followed by antiresorptive therapy, usually denosumab 60 mg subcutaneously every six months or an oral bisphosphonate, to preserve the BMD gains achieved with romosozumab. Guidance on sequential therapy following anabolic agents is covered in the AACE/ACE Clinical Practice Guidelines for Diagnosis and Treatment of Postmenopausal Osteoporosis.

Commercial Insurance Coverage in Oregon

Most commercial plans operating in Oregon, including Moda Health, PacificSource, Providence Health Plan, and the PEBB/OEBB plans for state employees, cover romosozumab on their specialty tier. That means cost sharing is typically 20 to 30% of the negotiated rate after meeting the specialty drug deductible, which commonly runs $500 to $2,000 per year. Without the savings card, a commercially insured Oregon patient might face $300 to $600 in monthly out-of-pocket costs at the deductible phase.

Step Therapy and How to Overcome It

Commercial plans almost always require step therapy. The patient must have documented:

1. Failure of alendronate (typically 70 mg weekly) for at least 12 months
2. Failure of risedronate (35 mg weekly or 150 mg monthly) OR documented intolerance or contraindication to oral bisphosphonates
3. A T-score meeting the plan's threshold (often -2.5 at spine or hip, or -2.0 with a fragility fracture)

Oregon law (ORS 743B.475) gives patients the right to request a step-therapy exemption if they can demonstrate that the required prior-drug caused an adverse event, is contraindicated, or was previously tried and failed. Clinicians should attach the DXA report, fracture history, and any prior adverse drug event documentation to the exemption request. A well-documented exemption request cuts average approval time from 14 days to approximately 5 to 7 days at most Oregon commercial plans.

Medical Benefit vs. Pharmacy Benefit in Oregon

Where romosozumab is administered matters for cost. When a clinician administers the injection in-office, the claim processes under the medical benefit (CPT code J3111, 1 mg; 210 units per dose). Office-based administration often has lower cost sharing for patients with good medical-benefit coverage but can be more burdensome to obtain. Specialty pharmacy dispensing processes under the pharmacy benefit. Oregon patients should call their plan's specialty pharmacy line and ask which routing minimizes their out-of-pocket cost before the first dose is ordered.

Amgen and UCB Patient Savings Programs

Amgen and UCB co-market Evenity and jointly run the Evenity Co-pay Assistance Program for commercially insured U.S. Patients. Program terms are described on the manufacturer's support page, with clinical eligibility linked to the FDA label.

How the Savings Card Works

Eligible commercially insured Oregon patients can pay as little as $0 per month. The program covers the patient cost-share portion after insurance pays its share. Key eligibility rules:

• Patient must have commercial insurance (not Medicaid, Medicare Part D, or any federally funded benefit)
• Patient must be a U.S. Resident
• Income caps may apply; the program periodically adjusts limits
• The benefit applies to up to 12 doses per calendar year, matching the approved treatment course

Oregon patients who are Medicare beneficiaries cannot use the commercial savings card due to federal anti-kickback statutes. Those patients should ask their clinician about the Amgen Safety Net Foundation, which provides free product to uninsured or underinsured patients who meet income requirements (generally at or below 500% of the federal poverty level).

Applying for the Program

The prescribing clinician or their office staff can enroll through the Amgen FIRST Step program. Enrollment typically takes 5 to 10 business days. Patients should confirm the savings card is activated before picking up the first dose, since retroactive reimbursement is not guaranteed under the current program terms.

Compounded Romosozumab in Oregon: Legal Status and Safety

Compounded romosozumab is available through licensed 503A compounding pharmacies in Oregon. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed pharmacists may compound drugs, including biologics and peptides, for individual patients based on a valid prescription from a licensed prescriber. The FDA's compounding oversight framework is published at fda.gov.

What 503A Compounding Means for Oregon Patients

A 503A pharmacy compounds for individual patients, not in bulk for wholesale distribution. Each prescription is patient-specific. Oregon Board of Pharmacy licensing requirements apply, and the compounding pharmacy must use pharmaceutical-grade active pharmaceutical ingredients (APIs). The reported cash cost for compounded romosozumab at select Oregon 503A pharmacies in 2026 is approximately $0 to significantly below the Amgen list price, depending on the pharmacy and the quantity compounded.

Regulatory Cautions

Compounded romosozumab is not FDA-approved. The FDA has not evaluated compounded versions for safety, purity, or potency on an individual-pharmacy basis. Romosozumab is a monoclonal antibody, a complex biologic that requires precise manufacturing conditions. Patients and prescribers should verify that any 503A pharmacy compounding romosozumab uses third-party tested APIs and provides a certificate of analysis (COA) with each lot. The Oregon Board of Pharmacy can confirm a pharmacy's active license at pharmacy.oregon.gov. NCBI provides background on the pharmacology of sclerostin inhibition relevant to assessing compounded formulations.

Prescribers bear clinical and legal responsibility for recommending a compounded biologic in place of an FDA-approved product. Many liability carriers require documentation of informed consent when compounded biologics are prescribed.

Clinical Evidence Supporting Romosozumab Use

ARCH Trial: Romosozumab vs. Alendronate

The ARCH trial (N=4,093, published in NEJM 2017) compared romosozumab 210 mg monthly for 12 months followed by alendronate versus alendronate alone in postmenopausal women with osteoporosis and a prior vertebral fracture. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% (6.2% vs. 11.9%; relative risk 0.52; 95% CI 0.40 to 0.66; P<0.001) [2]. Clinical nonvertebral fractures were reduced by 19% (8.7% vs. 10.6%; hazard ratio 0.81; 95% CI 0.66 to 0.99; P=0.04) [2].

Cardiovascular events were numerically higher in the romosozumab group (2.5% vs. 1.9%), which led to the FDA boxed warning. Clinicians must screen for prior MI or stroke before prescribing. Full ARCH data are indexed on PubMed.

FRAME Trial: Romosozumab vs. Placebo

The FRAME trial (N=7,180) demonstrated that romosozumab 210 mg monthly for 12 months reduced new vertebral fractures by 73% at 12 months (0.5% vs. 1.8%; P<0.001) and by 75% at 24 months after transition to denosumab [1]. Lumbar spine BMD increased 13.3% from baseline at 12 months [1]. FRAME data are available via PubMed.

AACE Guideline Recommendations

The American Association of Clinical Endocrinology 2020 guidelines on postmenopausal osteoporosis state: "In patients at very high fracture risk, anabolic therapy (teriparatide, abaloparatide, or romosozumab) is recommended as initial therapy, followed by antiresorptive therapy." Full guideline text is available at endocrine.org. This recommendation directly supports the use of romosozumab as first-line therapy in Oregon patients who qualify as very high risk, rather than requiring bisphosphonate failure first.

Clinicians in Oregon who believe their patient qualifies for first-line anabolic therapy should cite the AACE guideline in any commercial insurance step-therapy exemption request. The guideline language gives medical reviewers a clear basis to waive the bisphosphonate step in documented very-high-risk cases.

Telehealth Prescribing of Romosozumab in Oregon

Oregon law allows telehealth prescribing of controlled and non-controlled substances when a valid prescriber-patient relationship exists. Romosozumab is not a controlled substance, so telehealth prescribing faces fewer barriers. Oregon's telehealth prescribing framework aligns with guidance published by HHS and the NIH on expanded telehealth access.

A prescriber may evaluate a patient via telehealth, review DXA reports and labs electronically, and send a romosozumab prescription to a specialty pharmacy. The patient then self-administers the subcutaneous injection at home or visits a local clinic for office administration. Telehealth does not eliminate the need for baseline labs (serum calcium, 25-OH vitamin D) or DXA documentation; it simply allows those results to be reviewed remotely.

Oregon-licensed telehealth clinics and direct-to-patient platforms operating in Oregon must hold an Oregon DEA registration and a valid Oregon prescriber license. Patients using HealthRX or similar platforms should confirm the prescribing clinician holds an Oregon license before proceeding.

Sequential Therapy After Romosozumab

Romosozumab's BMD gains are lost if antiresorptive therapy is not started promptly after the 12th dose. The AACE guidelines and the 2022 American Society for Bone and Mineral Research (ASBMR) position statement both specify that a bisphosphonate or denosumab should begin within 30 days of the last romosozumab injection. ASBMR position statements are archived at ncbi.nlm.nih.gov.

Denosumab 60 mg every six months is the most common sequential choice in clinical practice. Alendronate 70 mg weekly is the preferred oral option when denosumab is cost-prohibitive. Patients on OHP who received romosozumab under a PA should have the sequential antiresorptive agent addressed in the same or an adjacent PA request to avoid a gap in treatment. A treatment gap exceeding 60 days after the final romosozumab dose may result in rapid bone loss. PubMed data on the anabolic window and rebound phenomenon with sclerostin inhibitors support this clinical timeline.

Baseline Labs and Monitoring Requirements

Before starting romosozumab, clinicians should obtain:

• Serum calcium (hypocalcemia is a contraindication)
• 25-hydroxyvitamin D (supplement to at least 30 ng/mL before initiating)
• Creatinine and eGFR (dose adjustment not required for mild-moderate renal impairment, but severe impairment increases hypocalcemia risk)
• DXA at lumbar spine and total hip (baseline for response monitoring)
• Cardiovascular history screen (MI, stroke, TIA in prior 12 months = contraindication)

Repeat DXA at 12 months after completing the course quantifies response. A lumbar spine BMD increase of 5% or more from baseline is considered a meaningful response by AACE criteria. The NIH Osteoporosis Resource Center provides patient-level guidance on DXA interpretation that aligns with these thresholds.

Calcium supplementation of 1,000 to 1,200 mg daily and vitamin D supplementation of 800 to 1,000 IU daily are recommended throughout the treatment course to reduce hypocalcemia risk. Supplementation thresholds are referenced in the NIH Office of Dietary Supplements calcium fact sheet.